ObjectiveTo investigate the clinical efficacy of hepatic arterial infusion with endostar combined with chemoembolization for late-stage liver cancer. MethodsSeventy-eight patients with Advanced liver cancer were enrolled, including 39 cases treated with chemoembolization(control group) and 39 cases treated with hepatic arterial infusion with endostar combined with chemoembolization (observation group). The total therapeutic effective rate, survival rate, alpha-fetoprotein (AFP), cellular immune function and quality of life were compared between the two groups. ResultsThe clinical efficacy of the observation group was superior to that of the control group（P＜0.05）. Compared to the control group, the levels of CD3, CD4 and NK cells and the ratio of CD4/CD8 were higher, but AFP level was lower in the observation group（P＜0.05）. The survival rate of the observation group was higher than that of the control group（P＜0.05）. The scores of 5 types of function, 3 symptoms and total health condition were higher in the observation group compared to the control group（P＜0.05）. ConclusionApplication of hepatic arterial infusion with endostar combined with chemoembolization can obtain a good efficacy for advanced liver cancer, not only can improve the AFP level and cellular immune function, but also improve the survival rate and quality of life. It is worthy of clinical promotion and application.

无